What type of study is this?

August 20, 2025Open Access

Figure 2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

Significant tumor fraction changes correlated with improved clinical outcomes in patients treated with immune checkpoint inhibitors.
Kaplan–Meier analysis showed a strong association between tumor fraction decrease and better rwPFS, with P-values highlight its significance.
Observational analysis using a real-world dataset identifies candidate thresholds for tumor fraction changes indicating treatment response.
These findings support potential biomarker development for personalized immunotherapy approaches in cancer management.

Abstract

A and B, Candidate thresholds for TF change indicating MR and nMR among the patients in whom either T0 or T1 were quantifiable (n = 459). A, Forest plot for various TF changes (B) Kaplan–Meier analysis of rwPFS by select candidate thresholds across the full dataset. Log-rank test between groups: 100% vs. any decrease, P P = 0.01; 100% decrease vs. 80% decrease, P = 0.04; 100% decrease vs. any increase, P P P

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Samantha I. Liang

Zoe Quandt

Sara Wienke

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Figure 2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study